EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen
Open Access
- 22 April 2016
- journal article
- research article
- Published by Wiley in The Journal of Pathology
- Vol. 239 (3), 320-334
- https://doi.org/10.1002/path.4729
Abstract
Chordoma is a rare malignant bone tumour with a poor prognosis and limited therapeutic options. We undertook a focused compound screen (FCS) against 1097 compounds on three well-characterized chordoma cell lines; 154 compounds were selected from the single concentration screen (1 µm), based on their growth-inhibitory effect. Their half-maximal effective concentration (EC50) values were determined in chordoma cells and normal fibroblasts. Twenty-seven of these compounds displayed chordoma selective cell kill and 21/27 (78%) were found to be EGFR/ERBB family inhibitors. EGFR inhibitors in clinical development were then studied on an extended cell line panel of seven chordoma cell lines, four of which were sensitive to EGFR inhibition. Sapitinib (AstraZeneca) emerged as the lead compound, followed by gefitinib (AstraZeneca) and erlotinib (Roche/Genentech). The compounds were shown to induce apoptosis in the sensitive cell lines and suppressed phospho-EGFR and its downstream pathways in a dose-dependent manner. Analysis of substituent patterns suggested that EGFR-inhibitors with small aniline substituents in the 4-position of the quinazoline ring were more effective than inhibitors with large substituents in that position. Sapitinib showed significantly reduced tumour growth in two xenograft mouse models (U-CH1 xenograft and a patient-derived xenograft, SF8894). One of the resistant cell lines (U-CH2) was shown to express high levels of phospho-MET, a known bypass signalling pathway to EGFR. Neither amplifications (EGFR, ERBB2, MET) nor mutations in EGFR, ERBB2, ERBB4, PIK3CA, BRAF, NRAS, KRAS, PTEN, MET or other cancer gene hotspots were detected in the cell lines. Our findings are consistent with the reported (p-)EGFR expression in the majority of clinical samples, and provide evidence for exploring the efficacy of EGFR inhibitors in the treatment of patients with chordoma and studying possible resistance mechanisms to these compounds in vitro and in vivo. © 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.Funding Information
- Chordoma UK (166854)
- Sarcoma UK (008.2012)
- Rosetrees Trust (M23-F1)
- RNOH NHS Trust
- Austrian Science Fund (J3640, 2014-2016)
- Marietta-Blau (ICM-2012-01605)
- OeAD (2013)
- Cancer Research UK
This publication has 85 references indexed in Scilit:
- Molecular targeted therapies in advanced or metastatic chordoma patients: Facts and hypothesesCritical Reviews in Oncology/Hematology, 2015
- Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review2015
- Population pharmacokinetics of HM781-36 (poziotinib), pan-human EGF receptor (HER) inhibitor, and its two metabolites in patients with advanced solid malignanciesCancer Chemotherapy and Pharmacology, 2014
- Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2014
- Genotyping Cancer-Associated Genes in Chordoma Identifies Mutations in Oncogenes and Areas of Chromosomal Loss Involving CDKN2A, PTEN, and SMARCB1PLOS ONE, 2014
- Erlotinib Inhibits Growth of a Patient-Derived Chordoma XenograftPLOS ONE, 2013
- Epidermal growth factor receptor (EGFR) expression and mutations in the EGFR signaling pathway in correlation with anti-EGFR therapy in head and neck squamous cell carcinomasNeoplasma, 2012
- Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomasNeuro-Oncology, 2010
- Aberrant Hyperactivation of Akt and Mammalian Target of Rapamycin Complex 1 Signaling in Sporadic ChordomasClinical Cancer Research, 2009
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences of the United States of America, 2005